COMMUNIQUÉ DE PRESSE publié le 01/10/2024 à 14:30, il y a 1 année 8 mois Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer Jaguar Health, Inc. announces positive results for crofelemer in breast cancer patients from OnTarget trial, to be presented at an oncology conference with potential for future submissions. Crofelemer also shows promise in IBS-D patients Crofelemer Jaguar Health Breast Cancer IBS-D Oncology Conference
BRÈVE publiée le 26/09/2024 à 16:05, il y a 1 année 9 mois Jaguar Health Advisory Board Member to Present at ASCO Quality Care Symposium Jaguar Health ASCO Symposium Cancer QoL Survey Supportive Care Stacey Tinianov
BRÈVE publiée le 26/09/2024 à 16:05, il y a 1 année 9 mois Un membre du conseil consultatif de Jaguar Health fera une présentation au symposium ASCO sur la qualité des soins Santé Jaguar Stacey Tinianov Symposium De L'ASCO Enquête Sur La Qualité De Vie Liée Au Cancer Soins De Soutien
COMMUNIQUÉ DE PRESSE publié le 26/09/2024 à 16:00, il y a 1 année 9 mois Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Jaguar Health, Inc. focuses on cancer supportive care & quality of life for patients. ASCO presentation on methodologies for 'More Than a Diagnosis' survey sponsored by Napo Pharmaceuticals Napo Pharmaceuticals Quality Of Life Jaguar Health Inc. Cancer Supportive Care ASCO Presentation
BRÈVE publiée le 25/09/2024 à 14:35, il y a 1 année 9 mois Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference Napo Pharmaceuticals Investor Conference Webcast Jaguar Health Gastrointestinal Medicines
BRÈVE publiée le 25/09/2024 à 14:35, il y a 1 année 9 mois Jaguar Health participera à la conférence des investisseurs de Lytham Partners à l'automne 2024 Webcast Conférence Des Investisseurs Santé Jaguar Napo Pharmaceutique Médicaments Gastro-intestinaux
COMMUNIQUÉ DE PRESSE publié le 25/09/2024 à 14:30, il y a 1 année 9 mois Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 Jaguar Health's CEO Lisa Conte to participate in webcasted presentation and one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference Jaguar Health Lisa Conte Lytham Partners Investor Meetings Webcasted Presentation
BRÈVE publiée le 24/09/2024 à 16:05, il y a 1 année 9 mois Jaguar Health Highlights Focus on Cancer Supportive Care at ASTRO Annual Meeting Jaguar Health Gelclair Oral Mucositis Cancer Supportive Care ASTRO Annual Meeting
BRÈVE publiée le 24/09/2024 à 16:05, il y a 1 année 9 mois Jaguar Health met l'accent sur les soins de soutien en oncologie lors de la réunion annuelle de l'ASTRO Santé Jaguar Gelclair Mucite Buccale Réunion Annuelle De L'ASTRO Soins De Soutien En Cancérologie
COMMUNIQUÉ DE PRESSE publié le 24/09/2024 à 16:00, il y a 1 année 9 mois Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch Jaguar Health's Napo Pharmaceuticals to showcase Gelclair, an FDA-approved oral mucositis prescription product, at ASTRO Annual Meeting. Gelclair offers pain relief and support for cancer patients Napo Pharmaceuticals Jaguar Health Gelclair Oral Mucositis ASTRO Annual Meeting
Publié le 27/06/2026 à 00:00, il y a 1 heure 44 minutes Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Publié le 26/06/2026 à 23:00, il y a 2 heures 44 minutes Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Publié le 26/06/2026 à 22:50, il y a 2 heures 54 minutes Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Publié le 26/06/2026 à 22:15, il y a 3 heures 29 minutes Revive Therapeutics Announces Proposed Private Placement
Publié le 27/06/2026 à 00:05, il y a 1 heure 39 minutes EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Publié le 27/06/2026 à 00:04, il y a 1 heure 40 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 2 heures 8 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 2 heures 8 minutes EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Publié le 26/06/2026 à 23:27, il y a 2 heures 17 minutes EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE